Chair
Member
Audit Committee Position

David R. Hoffmann

David R. Hoffman has served as a member of Molecular Templates’ Board of Directors since August 2017. Previously, Mr. Hoffman served on Threshold Pharmaceutical’s Board of Directors since April 2007. Mr. Hoffmann is retired from ALZA Corporation (now a Johnson & Johnson company) where he held the positions of Vice President and Treasurer from 1992 until his retirement in October 2002, Vice President of Finance from 1982 to 1992 and Director of Accounting/Finance from 1976 to 1982. Mr. Hoffmann is currently Chief Executive Officer of Hoffmann Associates, a multi-group company specializing in cruise travel and financial and benefit consulting. He serves as Chairman of the board of directors of DURECT Corporation. Mr. Hoffmann holds a Bachelor of Science in Business Administration from the University of Colorado.

Chair

David Hirsch, M.D., Ph.D.

David Hirsch has served on Molecular Templates’ Board of Directors since August 2017. Dr. Hirsch is a Managing Director and Founder of Longitude Capital. Prior to Longitude Capital, Dr. Hirsch was a Vice President of Pequot Capital Management, where he worked in the life sciences practice. Before Pequot Capital Management, Dr. Hirsch was an Engagement Manager in the pharmaceutical practice of McKinsey & Company. While at McKinsey & Company, he worked with many large pharmaceutical companies across a range of projects including clinical and commercial strategies, M&A evaluations, portfolio prioritization and managed care strategy. Dr. Hirsch currently sits on the boards of Collegium Pharmaceutical, Inc. (COLL), Inflazome Ltd., Poseida Therapeutics, Inc., Rapid Micro Biosystems, Inc., Tricida, Inc., Velicept Therapetuics, Inc., and previously served on the board of directors of Civitas Therapeutics, Inc., Precision Therapeutics, Inc., and Zavante Therapeutics, Inc. Dr. Hirsch holds a Doctor of Philosophy in Biology from the Massachusetts Institute of Technology, an M.D. from Harvard Medical School and a Bachelor of Arts in Biology from The Johns Hopkins University.

Member

Scott Morenstein

Scott Morenstein has served as a member of Molecular Templates’ Board of Directors since August 2017. Mr. Morenstein serves as Managing Director of CAM Capital where he leads healthcare investing. CAM Capital was established in 2012 by Bruce Kovner following his retirement from Caxton Associates, the macro hedge fund he founded and managed from 1983 to 2011.

Before joining CAM Capital in 2013, Mr. Morenstein served as Managing Director at Valence Life Sciences and before that Principal at Caxton Advantage Venture Partners, which he joined in 2007. Prior to joining Caxton Advantage, Mr. Morenstein served as an investment banking associate and founding member of Seaview Securities. Mr. Morenstein began his career at Lehman Brothers as a healthcare investment banker and equity research analyst. Mr. Morenstein has more than 15 years’ experience in biopharmaceutical investing, equity research and investment banking.

Mr. Morenstein led CAM’s investment in and served as a Director of Celator Pharmaceuticals until its acquisition by Jazz Pharmaceuticals in July 2016. He was nominated as a Director of Synta Pharmaceuticals to advise the company as it explored strategic alternatives ultimately leading to a merger with Madrigal Pharmaceuticals. He served as a member of Gemin X’s Board until its acquisition by Cephalon. He currently serves as a Director of Velicept Therapeutics and Antios Therapeutics.

Mr. Morenstein received a Master of Business Administration from Harvard Business School and a Bachelor of Arts from the University of Pennsylvania with a degree in the Biological Basis of Behavior with a Concentration in the Physiology of Neural Systems.

Member

Audit Committee Charter

Download
Compensation Committee Position

Kevin Lalande

Kevin Lalande has served on Molecular Templates’ Board of Directors since March 2009. Mr. Lalande is a founder and Managing Director of Santé Ventures, a venture capital firm. Prior to founding Santé Ventures in 2006, Mr. Lalande spent seven years with Austin Ventures. Before joining Austin Ventures, Mr. Lalande was a management consultant with McKinsey & Company. Mr. Lalande holds a Bachelor of Science in Electrical and Computer Engineering from Brigham Young University and a Master of Business Administration with Highest Distinction from the Harvard Business School.

Chair

David Hirsch, M.D., Ph.D.

David Hirsch has served on Molecular Templates’ Board of Directors since August 2017. Dr. Hirsch is a Managing Director and Founder of Longitude Capital. Prior to Longitude Capital, Dr. Hirsch was a Vice President of Pequot Capital Management, where he worked in the life sciences practice. Before Pequot Capital Management, Dr. Hirsch was an Engagement Manager in the pharmaceutical practice of McKinsey & Company. While at McKinsey & Company, he worked with many large pharmaceutical companies across a range of projects including clinical and commercial strategies, M&A evaluations, portfolio prioritization and managed care strategy. Dr. Hirsch currently sits on the boards of Collegium Pharmaceutical, Inc. (COLL), Inflazome Ltd., Poseida Therapeutics, Inc., Rapid Micro Biosystems, Inc., Tricida, Inc., Velicept Therapetuics, Inc., and previously served on the board of directors of Civitas Therapeutics, Inc., Precision Therapeutics, Inc., and Zavante Therapeutics, Inc. Dr. Hirsch holds a Doctor of Philosophy in Biology from the Massachusetts Institute of Technology, an M.D. from Harvard Medical School and a Bachelor of Arts in Biology from The Johns Hopkins University.

Member

Compensation Committee Charter

Download
Nominating and Corporate Governance Committee Position

Kevin Lalande

Kevin Lalande has served on Molecular Templates’ Board of Directors since March 2009. Mr. Lalande is a founder and Managing Director of Santé Ventures, a venture capital firm. Prior to founding Santé Ventures in 2006, Mr. Lalande spent seven years with Austin Ventures. Before joining Austin Ventures, Mr. Lalande was a management consultant with McKinsey & Company. Mr. Lalande holds a Bachelor of Science in Electrical and Computer Engineering from Brigham Young University and a Master of Business Administration with Highest Distinction from the Harvard Business School.

Chair

David Hirsch, M.D., Ph.D.

David Hirsch has served on Molecular Templates’ Board of Directors since August 2017. Dr. Hirsch is a Managing Director and Founder of Longitude Capital. Prior to Longitude Capital, Dr. Hirsch was a Vice President of Pequot Capital Management, where he worked in the life sciences practice. Before Pequot Capital Management, Dr. Hirsch was an Engagement Manager in the pharmaceutical practice of McKinsey & Company. While at McKinsey & Company, he worked with many large pharmaceutical companies across a range of projects including clinical and commercial strategies, M&A evaluations, portfolio prioritization and managed care strategy. Dr. Hirsch currently sits on the boards of Collegium Pharmaceutical, Inc. (COLL), Inflazome Ltd., Poseida Therapeutics, Inc., Rapid Micro Biosystems, Inc., Tricida, Inc., Velicept Therapetuics, Inc., and previously served on the board of directors of Civitas Therapeutics, Inc., Precision Therapeutics, Inc., and Zavante Therapeutics, Inc. Dr. Hirsch holds a Doctor of Philosophy in Biology from the Massachusetts Institute of Technology, an M.D. from Harvard Medical School and a Bachelor of Arts in Biology from The Johns Hopkins University.

Member

Nominating and Corporate Governance Committee Charter

Download

David R. Hoffmann

David R. Hoffman has served as a member of Molecular Templates’ Board of Directors since August 2017. Previously, Mr. Hoffman served on Threshold Pharmaceutical’s Board of Directors since April 2007. Mr. Hoffmann is retired from ALZA Corporation (now a Johnson & Johnson company) where he held the positions of Vice President and Treasurer from 1992 until his retirement in October 2002, Vice President of Finance from 1982 to 1992 and Director of Accounting/Finance from 1976 to 1982. Mr. Hoffmann is currently Chief Executive Officer of Hoffmann Associates, a multi-group company specializing in cruise travel and financial and benefit consulting. He serves as Chairman of the board of directors of DURECT Corporation. Mr. Hoffmann holds a Bachelor of Science in Business Administration from the University of Colorado.

David Hirsch, M.D., Ph.D.

David Hirsch has served on Molecular Templates’ Board of Directors since August 2017. Dr. Hirsch is a Managing Director and Founder of Longitude Capital. Prior to Longitude Capital, Dr. Hirsch was a Vice President of Pequot Capital Management, where he worked in the life sciences practice. Before Pequot Capital Management, Dr. Hirsch was an Engagement Manager in the pharmaceutical practice of McKinsey & Company. While at McKinsey & Company, he worked with many large pharmaceutical companies across a range of projects including clinical and commercial strategies, M&A evaluations, portfolio prioritization and managed care strategy. Dr. Hirsch currently sits on the boards of Collegium Pharmaceutical, Inc. (COLL), Inflazome Ltd., Poseida Therapeutics, Inc., Rapid Micro Biosystems, Inc., Tricida, Inc., Velicept Therapetuics, Inc., and previously served on the board of directors of Civitas Therapeutics, Inc., Precision Therapeutics, Inc., and Zavante Therapeutics, Inc. Dr. Hirsch holds a Doctor of Philosophy in Biology from the Massachusetts Institute of Technology, an M.D. from Harvard Medical School and a Bachelor of Arts in Biology from The Johns Hopkins University.

Scott Morenstein

Scott Morenstein has served as a member of Molecular Templates’ Board of Directors since August 2017. Mr. Morenstein serves as Managing Director of CAM Capital where he leads healthcare investing. CAM Capital was established in 2012 by Bruce Kovner following his retirement from Caxton Associates, the macro hedge fund he founded and managed from 1983 to 2011.

Before joining CAM Capital in 2013, Mr. Morenstein served as Managing Director at Valence Life Sciences and before that Principal at Caxton Advantage Venture Partners, which he joined in 2007. Prior to joining Caxton Advantage, Mr. Morenstein served as an investment banking associate and founding member of Seaview Securities. Mr. Morenstein began his career at Lehman Brothers as a healthcare investment banker and equity research analyst. Mr. Morenstein has more than 15 years’ experience in biopharmaceutical investing, equity research and investment banking.

Mr. Morenstein led CAM’s investment in and served as a Director of Celator Pharmaceuticals until its acquisition by Jazz Pharmaceuticals in July 2016. He was nominated as a Director of Synta Pharmaceuticals to advise the company as it explored strategic alternatives ultimately leading to a merger with Madrigal Pharmaceuticals. He served as a member of Gemin X’s Board until its acquisition by Cephalon. He currently serves as a Director of Velicept Therapeutics and Antios Therapeutics.

Mr. Morenstein received a Master of Business Administration from Harvard Business School and a Bachelor of Arts from the University of Pennsylvania with a degree in the Biological Basis of Behavior with a Concentration in the Physiology of Neural Systems.

Kevin Lalande

Kevin Lalande has served on Molecular Templates’ Board of Directors since March 2009. Mr. Lalande is a founder and Managing Director of Santé Ventures, a venture capital firm. Prior to founding Santé Ventures in 2006, Mr. Lalande spent seven years with Austin Ventures. Before joining Austin Ventures, Mr. Lalande was a management consultant with McKinsey & Company. Mr. Lalande holds a Bachelor of Science in Electrical and Computer Engineering from Brigham Young University and a Master of Business Administration with Highest Distinction from the Harvard Business School.

David Hirsch, M.D., Ph.D.

David Hirsch has served on Molecular Templates’ Board of Directors since August 2017. Dr. Hirsch is a Managing Director and Founder of Longitude Capital. Prior to Longitude Capital, Dr. Hirsch was a Vice President of Pequot Capital Management, where he worked in the life sciences practice. Before Pequot Capital Management, Dr. Hirsch was an Engagement Manager in the pharmaceutical practice of McKinsey & Company. While at McKinsey & Company, he worked with many large pharmaceutical companies across a range of projects including clinical and commercial strategies, M&A evaluations, portfolio prioritization and managed care strategy. Dr. Hirsch currently sits on the boards of Collegium Pharmaceutical, Inc. (COLL), Inflazome Ltd., Poseida Therapeutics, Inc., Rapid Micro Biosystems, Inc., Tricida, Inc., Velicept Therapetuics, Inc., and previously served on the board of directors of Civitas Therapeutics, Inc., Precision Therapeutics, Inc., and Zavante Therapeutics, Inc. Dr. Hirsch holds a Doctor of Philosophy in Biology from the Massachusetts Institute of Technology, an M.D. from Harvard Medical School and a Bachelor of Arts in Biology from The Johns Hopkins University.

Kevin Lalande

Kevin Lalande has served on Molecular Templates’ Board of Directors since March 2009. Mr. Lalande is a founder and Managing Director of Santé Ventures, a venture capital firm. Prior to founding Santé Ventures in 2006, Mr. Lalande spent seven years with Austin Ventures. Before joining Austin Ventures, Mr. Lalande was a management consultant with McKinsey & Company. Mr. Lalande holds a Bachelor of Science in Electrical and Computer Engineering from Brigham Young University and a Master of Business Administration with Highest Distinction from the Harvard Business School.

David Hirsch, M.D., Ph.D.

David Hirsch has served on Molecular Templates’ Board of Directors since August 2017. Dr. Hirsch is a Managing Director and Founder of Longitude Capital. Prior to Longitude Capital, Dr. Hirsch was a Vice President of Pequot Capital Management, where he worked in the life sciences practice. Before Pequot Capital Management, Dr. Hirsch was an Engagement Manager in the pharmaceutical practice of McKinsey & Company. While at McKinsey & Company, he worked with many large pharmaceutical companies across a range of projects including clinical and commercial strategies, M&A evaluations, portfolio prioritization and managed care strategy. Dr. Hirsch currently sits on the boards of Collegium Pharmaceutical, Inc. (COLL), Inflazome Ltd., Poseida Therapeutics, Inc., Rapid Micro Biosystems, Inc., Tricida, Inc., Velicept Therapetuics, Inc., and previously served on the board of directors of Civitas Therapeutics, Inc., Precision Therapeutics, Inc., and Zavante Therapeutics, Inc. Dr. Hirsch holds a Doctor of Philosophy in Biology from the Massachusetts Institute of Technology, an M.D. from Harvard Medical School and a Bachelor of Arts in Biology from The Johns Hopkins University.